ADONIS AL-BOTROS: Open Payments
NPI 1316994551 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,217 in 191 payments from 18 companies in 2025. Trend: 2023 $12,029 · 2024 $6,744 · 2025 $3,217
Food & beverage: $3,008Education: $209
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $632 |
| Alkermes, Inc. | 15 | $316 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $309 |
| ABBVIE INC. | 28 | $268 |
| Otsuka America Pharmaceutical, Inc. | 16 | $230 |
| Vanda Pharmaceuticals Inc. | 13 | $226 |
| Neurocrine BioSciences, Inc. | 18 | $225 |
| Bausch Health US, LLC | 11 | $223 |
| Janssen Pharmaceuticals, Inc | 12 | $197 |
| Axsome Therapeutics, Inc. | 8 | $181 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, FANAPT, INGREZZA, REXULTI, UZEDY, AUSTEDO XR.
Industry payments across OK — which companies pay providers there.
